How to buy Altimmune stock (ALT)

Altimmune is a biotechnology business based in the US. Altimmune shares (ALT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $9.03 – a decrease of 6.33% over the previous week. Altimmune employs 59 staff and has a trailing 12-month revenue of around $52,000.

Our top picks for where to buy Altimmune stock

Buy Altimmune stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Altimmune stock price (NASDAQ: ALT)

Use our graph to track the performance of ALT stocks over time.

Altimmune shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$9.03
52-week range	$5.28 - $14.84
50-day moving average more info button	$7.76
200-day moving average more info button	$7.47
Wall St. target price	$22.86
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.57

Is it a good time to buy Altimmune stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Altimmune price performance over time

Historical closes compared with the close of $9 from 2024-12-16

1 week (2024-12-12)	4.77%
1 month (2024-11-20)	11.80%
3 months (2024-09-19)	18.89%
6 months (2024-06-18)	52.28%

1 year (2023-12-19)	10.29%
2 years (2022-12-19)	-12.28%
3 years (2021-12-17)	9.36
5 years (2019-12-19)	405.62%

Altimmune financials

Revenue TTM	$52,000
Gross profit TTM	$-70,520,000
Return on assets TTM	-39.56%
Return on equity TTM	-72.96%
Profit margin	0%
Book value	$1.88
Market Capitalization more info button	$561.9 million

TTM: trailing 12 months

Altimmune share dividends

We're not expecting Altimmune to pay a dividend over the next 12 months.

Have Altimmune's shares ever split?

Altimmune's shares were split on a 1:30 basis on 13 September 2018 . So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Altimmune shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Altimmune shares which in turn could have impacted Altimmune's share price.

Altimmune share price volatility

Over the last 12 months, Altimmune's shares have ranged in value from as little as $5.275 up to $14.84. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Altimmune's is 0.072. This would suggest that Altimmune's shares are less volatile than average (for this exchange).

Altimmune overview

Altimmune, Inc. , a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015.

Frequently asked questions

null
What percentage of Altimmune is owned by insiders or institutions?
Currently 0.794% of Altimmune shares are held by insiders and 56.678% by institutions. How many people work for Altimmune?
Latest data suggests 59 work at Altimmune. When does the fiscal year end for Altimmune?
Altimmune's fiscal year ends in December. Where is Altimmune based?
Altimmune's address is: 910 Clopper Road, Gaithersburg, MD, United States, 20878 What is Altimmune's ISIN number?
Altimmune's international securities identification number is: US02155H2004 What is Altimmune's CUSIP number?
Altimmune's Committee on Uniform Securities Identification Procedures number is: 42224H203